Immunosuppression or immunostimulation for aplastic anemia? A blast from the past.
Scheinberg
Phillip
P
Hematology Branch, National Heart, Lung and Blood Institute, 10 Center Drive, Building 10 CRC, Room 3-5140, MSC 1202, Bethesda, MD 20892-1202, USA. Scheinbp@nhlbi.nih.gov
D000741:Anemia, Aplastic / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D015551:Autoimmunity / Q000187:drug effects; D017690:Cell Transplantation; D016572:Cyclosporine / Q000627:therapeutic use; D006410:Hematopoiesis; D006801:Humans; D007114:Immunization / Q000379:methods; D007165:Immunosuppression Therapy; D007376:Interleukin-2 / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects / Q000378:metabolism* / Q000637:transplantation; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D010835:Phytohemagglutinins / Q000276:immunology / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D007376:Interleukin-2; D010835:Phytohemagglutinins; D016572:Cyclosporine